biote Corp. (BTMD) Q3 2025 10-Q Quarterly Report
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
Medicinal Chemicals & Botanical ProductsSEC EDGAR biote Corp. (BTMD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
biote Corp. Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • No quarterly revenue or YoY change data disclosed in MD&A
- • No profitability or margin figures reported for the quarter or YoY comparisons
Risk Factors
- • New risk: Share repurchase program authorized up to $20.0M, with $11.0M remaining as of Sept 30, 2025, introducing potential stock price volatility
- • Material update: Rising tariffs on estradiol from China and trocars from Pakistan increasing raw material costs and supply chain risks
biote Corp. Q3 2025 Quarterly FinancialsXBRL
Revenue
$48M
▼ -6.7% YoY▼ -1.9% QoQ
Net Income
$8M
▲ +4.4% YoY▲ +157.1% QoQ
Operating Margin
17.2%
▼ -647bp YoY▼ -479bp QoQ
Net Margin
17.1%
▲ +180bp YoY▲ +1056bp QoQ
ROE
-11.3%
Total Assets
$111M
EPS (Diluted)
$0.22
▼ -4.3% YoY▲ +144.4% QoQ
Operating Cash Flow
$14M
▼ -9.5% YoY▲ +98.6% QoQ
Source: XBRL data from biote Corp. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on biote Corp.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.